Focus  by Shouval, Daniel
FocusFocus
Daniel Shouval
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beads: new insight into the biologic effects of tumor ablationTransarterial chemoembolization (TACE) was the ﬁrst loco-regio-
nal ablative therapy for hepatocellular carcinoma (HCC), devel-
oped in Japan in the early 1980s [1,2]. The procedure involved
intra arterial injection into the hepatic artery of a suspension of
the radiologic contrast agent lipiodol (derived from poppy seed
oil) mixed with adriamycin [2]. The technique was rapidly
adopted by Japanese hepatologists and oncologists [2,3] but it
took almost two decades until it was accepted in the Western
hemisphere [4,5]. The procedure underwent a number of modiﬁ-
cations over the years including the introduction of additional
chemotherapeutic agents instead of adriamycin as well as bland
particle embolization intended to induce tumor ischemia and
necrosis without using a chemotherapeutic agent. Two meta-
analyses have failed to show a signiﬁcant survival difference
between embolization alone and TACE, although there was a
trend toward longer survival with TACE [6,7]. By now, TACE is
used worldwide for treatment of both unresectable and recurrent
HCC as well as for down-staging of tumor volume pending sur-
gery [8,9]. Although TACE has now been in use for over 20 years,
surprisingly, very little is known on the mechanism of selective
lipiodol and adriamycin uptake by transformed hepatocytes. Fur-
thermore, the pharmacokinetics of chemotherapeutic agents
used in TACE and the degree of their release into the systemic cir-
culation have received very little attention [10,11].
Recently, the conventional TACE technique was reﬁned
through the development of drug eluting beads (DEB) [12].
There are currently two types of DEBs consisting of sulfonate
modiﬁed polyvinyl alcohol hydrogel or sodium acrylate and vinyl
alcohol co-polymers. These microspheres have the ability to
absorb doxorubicin from solution and, in contrast to lipiodol con-
taining emulsions, release it in a controlled and sustained fashion
with minimal release into the systemic circulation [13]. Further-
more, the treatment leads to a more distal and most likely more
reproducible ischemic effect in the liver as compared to emboli-
zation (i.e. with gelfoam). The clinical utility of DEBs has recently
been evaluated in a multi-center European RCT comparing con-
ventional TACE (with lipiodol) vs. doxorubicin eluting beads
administered to HCC patients. Tumor response rates reached
52% and 44% in patients treated with DEB and conventional TACE
respectively but time for tumor progression was similar [14].
Drug related adverse events were signiﬁcantly lower in DEBJournal of Hepatology 20
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a smaller scale study from Belgium [15]. The improved tolerabil-
ity of DEB mediated ablation as compared to conventional TACE
and the more controlled manner of this procedure is therefore
attracting the attention of clinicians involved in the care of HCC
patients. Consequently, it becomes important to understand the
mechanism and pathophysiology involved in DEB treatment for
HCC. Fortunately, and in contrast to the lack of adequate pre-
clinical studies in the early days of TACE, DEBs containing
doxorubicin underwent preclinical evaluation in animal model
systems [16–18]. Yet, data obtained in animal models may not
be completely applicable to humans.
In the present issue of the Journal, Namur and co-workers
have studied by microspectroﬂuorimetry the doxorubicin
concentrations in six explants of HCC patients who underwent
liver transplantation within 8 h to 36 days following treatment
by TACE with doxorubicin eluting beads (DEBOX, diameter
100–300 lm, 75–150 mg doxorubicin). Tissue injury was
assessed using histological techniques. The investigators were
able to verify that doxorubicin was indeed detectable in the
tissue surrounding the microspheres and the occluded vessels
up to a distance of 1.2 mm, while the concentration of the chemo-
therapeutic agent dropped progressively from a mean of 5 lm on
the date of liver transplantation to 0.65 lm 1month after TACE.
Furthermore, the drug concentration was similar in tumor
remnants and the perivascular tissue. The mean distance of bead
penetration into the tumor was 3.8 ± 3.7 mm. The report contains
additional important information on the penetrance and distribu-
tion of DEBs and doxorubicin. This paper should be of interest to
hepatologists, radiologists, oncologists, and surgeons involved in
the care of patients with HCC. The investigators have captured a
golden opportunity to examine the local effects of TACE using
DEBs. The obtained results conﬁrm the hypothesis that doxorubi-
cin released from the DEBs is indeed delivered into the tumor as
well as its surrounding, where potential satellites may rise. Peri-
vascular treatment induced necrosis was observed in only 37 and
40% of cases tested at 9–14 and 32–36 days, respectively follow-
ing treatment. This observation is not surprising. Previous expe-
rience with lipiodol based TACE suggests that one session of
TACE is rarely sufﬁcient to lead to complete necrosis and ablation
of even relatively small HCC lesions. Therefore, repeated sessions
of DEBs based TACE may be necessary. This interesting and
important study has a number of limitations, including the rela-
tively small number of explants which were available for testing
as well as the retrospective design which required the use of
formaldehyde ﬁxed tissue instead of a fresh frozen one. Finally,
the results cannot be used to conﬁrm the superiority of DEBs11 vol. 55 j 1169–1170
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based TACE over embolization alone or lipiodol–chemoemboliza-
tion. Yet, these data conﬁrm several pre-clinical observations in
animal models and justify further assessment of DEBs in clinical
practice.Conﬂict of interest
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